Obituaries
PGe
PG Store
Archives
Classifieds
Classified
Events
Jobs
Real Estate
Legal Notices
Pets
MENU
SUBSCRIBE
LOGIN
REGISTER
LOG OUT
MY PROFILE
Home
News
Local
Sports
Opinion
A&E
Life
Business
Contact Us
NEWSLETTERS
MENU
ACCOUNT
Subscribe
Login
Register
Log out
My Profile
Subscriber Services
Search
SECTIONS
HOME
Homepage
This Just In
Chats
Weather
Traffic
Event Guide
PG Store
PGe
Video
Photos
The Digs
RSS Feeds
NEWS
News Home
COVID-19
World
Nation
State
Obituaries
News Obituaries
Politics
Education
Portfolio
Science
Health & Wellness
Environment
Aging Edge
Transportation
Faith & Religion
Crimes & Courts
Social Services
LOCAL
Local Home
Region
City
North
East
West
South
Washington
Westmoreland
The Neighborhood
Obituaries
Classifieds
Legal Notices
Real Estate
SPORTS
Sports Home
Steelers
Penguins
Pirates
Sports Columns
Gene Collier
Ron Cook
Joe Starkey
Paul Zeise
High School Sports
College Sports
Pitt
Penn State
WVU
NCAA
NFL
MLB
NBA
NHL
North Shore Drive Podcast
OPINION
Opinion Home
Editorials
Letters
Op-Ed Columns
PG Columnists
Insight
A&E
A&E Home
Celebrities
Movies
TV & Radio
Music
Concert Listings
Theatre & Dance
Art & Architecture
Books
Events
LIFE
Life Home
Food
Buying Here
Homes & Gardens
Style & Fashion
Travel
Restaurants
Seen
goodness
Random Acts of Kindness
Pets
Beer Me
Outdoors
Holidays
BUSINESS
Business Home
Your Money
Wheels
Workzone
Business Health
Tech News
Building PGH
Powersource
Business / Law
Top Workplaces
Business of Pittsburgh
Consumer Alerts
OTHER
PGe
NEWSLETTERS
PG STORE
ARCHIVES
CLASSIFIEDS
OBITUARIES
JOBS
LEGAL NOTICES
REAL ESTATE
CLASSIFIEDS
EVENTS
PETS
CONTACT US / FAQ
CONTACT US
ADVERTISING
CAREER OPPORTUNITIES
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
CRISPR Therapeutics AG - Common Shares
(NQ:
CRSP
)
48.91
-1.02 (-2.03%)
Streaming Delayed Price
Updated: 3:59 PM EDT, Mar 12, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about CRISPR Therapeutics AG - Common Shares
< Previous
1
2
...
9
10
11
12
13
14
15
16
17
...
35
36
Next >
3 Healthcare Stocks to Make You the Millionaire Next Door: 2024 Edition
↗
January 03, 2024
Healthcare stocks tend to be more mature and reliable, but a handful of innovators offer massive long-term upside.
Via
InvestorPlace
Better Risky Investment: Bluebird Bio vs. Shiba Inu
↗
January 03, 2024
Few investors dare to tread where the ice is known to be very thin.
Via
The Motley Fool
3 Biotech Stocks Set for Breakthroughs in 2024
↗
January 02, 2024
With groundbreaking advancements in new medicine and science, 2024 holds a promising future for these biotech stocks.
Via
InvestorPlace
2 gene-editing stocks reshaping hereditary disease treatments
January 02, 2024
Gene-editing companies are making headlines for the potential to reshape the future of healthcare and the treatment of hereditary diseases. The U.S. Federal
Via
MarketBeat
Here's How Much $100 Invested In CRISPR Therapeutics 5 Years Ago Would Be Worth Today
↗
January 01, 2024
Via
Benzinga
Could CRISPR Therapeutics Stock Help You Become a Millionaire?
↗
December 22, 2023
There are plenty of reasons to be optimistic about CRISPR's future.
Via
The Motley Fool
3 No-Brainer Growth Stocks to Buy for Less Than $100
↗
January 01, 2024
These businesses have promising futures and make for great investment options today.
Via
The Motley Fool
1 Cathie Wood Stock Worth Buying Hand Over Fist in 2024
↗
December 31, 2023
Ark Invest holds a hefty position in this gene-editing stock. Risk-tolerant investors may want to take a page from the fund's playbook on this name.
Via
The Motley Fool
2 Gene-Editing Stocks That Might Be the Next CRISPR Therapeutics
↗
December 31, 2023
Curing rare inherited illnesses could be a lucrative business model.
Via
The Motley Fool
2023 in Review: Nvidia, Interest Rates, Taylor Swift
↗
December 30, 2023
And a little bit of real estate insight.
Via
The Motley Fool
3 Stocks That Could Be Monster Winners in 2024
↗
December 30, 2023
Don't be surprised if these three stocks take off in the new year.
Via
The Motley Fool
AI and Automation Leaders for 2024: 7 Stocks to Stay Ahead of the Robot Uprising
↗
December 30, 2023
With the robotics revolution taking over multiple industries, investors have options.
Via
InvestorPlace
Topics
Artificial Intelligence
CRISPR Therapeutics sets sights on gene-editing cures for disease
December 27, 2023
On Dec. 8, 2023, Vertex Pharmaceuticals Inc. (NASDAQ: VRTX) announced the U.S. FDA approved its sickle-cell disease (SCD) treatment, Casgevy, for
Via
MarketBeat
3 Top Stocks to Buy Hand Over Fist Before the End of 2023
↗
December 25, 2023
These are ideal stocks to buy sooner rather than later.
Via
The Motley Fool
3 Healthcare Technology Stocks to Improve Lives in 2024
↗
December 25, 2023
Healthcare technology is one of 2024's top investment trends, and investors looking for long-term upside should check out these top stocks.
Via
InvestorPlace
1 Green Flag and 1 Red Flag for Bluebird Bio Stock
↗
December 23, 2023
The stock has been in the news lately.
Via
The Motley Fool
Cathie Wood Predicts Deflation In 2024, More AI And Tech Optimism — And Rate Cuts
↗
December 22, 2023
Cathie Wood believes deflation in 2024, aggressive rate cuts and technological progress will drive expansion.
Via
Benzinga
Topics
Artificial Intelligence
Economy
3 Money-Saving Tricks for Investing in Biotech Stocks in 2024
↗
December 22, 2023
Doing a little math and doing a little extra research can make a big difference.
Via
The Motley Fool
I'm Begging You to Buy Stocks Before January -- Here's Why
↗
December 22, 2023
Some studies have shown a pattern of market gains in the month of January.
Via
The Motley Fool
Up More Than 60% in 2023, Is It Too Late to Buy This Soaring Biotech Stock?
↗
December 22, 2023
The FDA's recent approval of CRISPR Therapeutics' first therapy is a step in the right direction.
Via
The Motley Fool
6 Words That Explain Why CRISPR Stock Isn't Soaring Despite the Recent FDA Approval for Its Gene-Editing Therapy
↗
December 21, 2023
Should you buy CRISPR's stock on the dip?
Via
The Motley Fool
Better Bull Market Buy: CRISPR Therapeutics vs. Pfizer Stock
↗
December 21, 2023
These stocks are currently going in different directions, but both could go up in a new bull market.
Via
The Motley Fool
Is Vertex Pharmaceuticals Sitting on a Gold Mine?
↗
December 21, 2023
Vertex shares have climbed about 40% this year.
Via
The Motley Fool
CRSP Stock Alert: CRISPR Therapeutics Is Losing Its Medical Chief
↗
December 20, 2023
The fate of Crispr and CRSP stock will be determined by the success of other drugs in the company's pipeline rather than Casgevy.
Via
InvestorPlace
3 Reasons to Buy CRISPR Therapeutics Stock Like There's No Tomorrow
↗
December 20, 2023
CRISPR Therapeutics stock has increased in the double digits this year.
Via
The Motley Fool
3 Genomics Stocks to Unlock the Future of Medicine
↗
December 19, 2023
Genomics stocks stand to surge in 2024 after the FDA approved the nation's first gene-editing therapeutic for clinical use.
Via
InvestorPlace
Better Growth Stock: Archer Aviation or Prime Medicine?
↗
December 19, 2023
Which of these innovation-themed growth stocks is the better buy?
Via
The Motley Fool
3 Healthcare Stocks That Could Help Make You a Millionaire
↗
December 19, 2023
These stocks each have reached an important turning point that could signal growth ahead.
Via
The Motley Fool
2 Stocks Profiting From Unstoppable Trends That Could Make You Rich
↗
December 18, 2023
It's important to choose companies involved in trends that have long-term potential.
Via
The Motley Fool
2 Stocks That Could Turn $1,000 Into $3,500 in 10 Years
↗
December 17, 2023
These businesses are exciting and can also lead to outsized long-term returns.
Via
The Motley Fool
< Previous
1
2
...
9
10
11
12
13
14
15
16
17
...
35
36
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.
TOP
Email a Story
Your e-mail:
Friends e-mail:
Submit
